

POLISH FINANCIAL SUPERVISION AUTHORITY

Current Report no. 19/2023

Date of preparation: 2023-07-11

Abbreviated name of the Issuer: MABION S.A.

Subject matter: Conclusion of an agreement for the supply of bioreactor set to the Company's manufacturing facility

Article 17(1) of MAR – confidential information.

Content of the Report:

The Management Board of Mabion S.A. ("Company") hereby informs that on 11 July 2023, it entered into an agreement with Global Life Sciences Solutions Poland Sp. z o.o. of the Cytiva group ("Supplier") on the purchase of a set of bioreactors of the following capacities – 10 litres (1 unit), 50 litres (2 units), 200 litres (2 units) and 2,000 litres (2 units), together with ancillary services ("Agreement").

Under the Agreement, the Supplier will manufacture, sell to and install at the Company a set of bioreactors under the brand name of "Cytiva Xcellerex XDR" in line with the specifications set out in the Agreement, together with associated documentation, commodities, software, and services. The planned date of delivery to the Company's manufacturing facility in Konstantynów Łódzki is Q3 2023, which will be followed by installation, qualification runs, and acceptance of the equipment. The net value of the Agreement is EUR 3.2 million.

The purchase of the above bioreactors will allow the Company to increase its current production capacity and is consistent with the Strategy of Mabion S.A. for 2023-2027 of which the Company informed in Current Report no. 7/2023 of 18 April 2023. As announced by the Company, the addition of bioreactors using classic mixing technology to the development and process equipment will enable a diversification of the bioreactor culture technology. As a result, Mabion will be able to offer both the already advanced orbital shaking technology owned by the Company as well as a technology based on the use of the conventional mixing system in bioreactors, which is the most common technology on the market). Due to this investment, the Company significantly strengthens its competitive position as a contract manufacturer ("CDMO") and gains the ability to acquire a new segment of clients whose products are developed using the conventional bioreactor technology.